Conference Coverage

Time to scrap LMWH for prevention of placenta-mediated pregnancy complications?


 

REPORTING FROM THSNA 2018


Revisiting the hypothetical case of a 32-year-old woman with prior severe preeclampsia who delivered at 32 weeks, Dr. Rodger said that he would “definitely not” recommend LMWH during her next pregnancy.

He acknowledged limitations of the systematic review, including the limited numbers of patients in subgroups and the large differences between single-center and multicenter trials. “We still can’t explain this, and it remains an open question that bugs me,” he said. “This has been seen in many disease areas. Empirically, single-centeredness leans toward positivity.”

He called for more research in women with recurrent pregnancy loss. Dr. Rodger reported having no financial disclosures.

Pages

Recommended Reading

Management of adnexal masses in pregnancy
MDedge Hematology and Oncology
Hemophilia carriers are at risk for abnormal bleeding
MDedge Hematology and Oncology
IVIg, corticosteroids appear comparable for ITP in pregnancy
MDedge Hematology and Oncology
Study highlights importance of genotyping in von Willebrand disease
MDedge Hematology and Oncology
VIDEO: Careful TKI hiatus makes CML pregnancy possible
MDedge Hematology and Oncology
Infections up the risk for pregnancy-associated stroke in preeclampsia
MDedge Hematology and Oncology
Folic acid fortification prevents millions of cases of anemia
MDedge Hematology and Oncology
Study advances noninvasive prenatal testing for hemophilia
MDedge Hematology and Oncology
MDedge Daily News: Why most heart failure may be preventable
MDedge Hematology and Oncology
Pregnant women in clinical trials: FDA questions how to include them
MDedge Hematology and Oncology